is now eighty-nine and his wife eightyfour years of age. He is mentally alert and carries on a conversation concerning current events, as well as reminiscences regarding his long and interesting life. He has outlived his doctor and his allotted time of three score years and ten and credits his longevity to both insulin and an adequate diet. Mr. Cowan's life should be an inspiration to all diabetic patients and a great satisfaction to the people still living who worked so diligently on insulin in the early days. He and his wife give daily thanks to those who saved his life and made it possible for him to live a normal, happy life. REFERENCEŜ ansum, W. D.; Blatherwick, N. R.; Smith, Florence H.; Long, M. Louisa; Maxwell, L. C; Hill, Elsie; McCarty, Ray; and Cryst, J. H.: The treatment of diabetes with insulin. Blatherwick, N. R.; and Bowden, Ruth: The use of high carbohydrate diets in the treatment of diabetes mellitus. J. A. M. A . 86:178-81, Jan. 16, 1926. 8 Blatherwick, N. R.; Sansum, W. D.; Bell, Marion; and Hill, Elsie: The insulin requirements of various diets.
In this issue of the Journal a paper by Ashmore, Cahill, Earle and Zottu 1 reports experiments in which the actions of insulin and tolbutamide in one and the same experimental preparation are compared. This paper prompts a review of the experimental evidence reported in the recent literature on the effects of the arylsulfonylureas in experimental and clinical diabetes. The conclusion seems to be warranted that the main action of these drugs is pancreatropic, bringing about a release of insulin from the P-cells. This conclusion is based on the unequivocal evidence that in the absence of the pancreas and in instances of complete alloxanization, as well as in the Houssay animal, no hypoglycemic action of the drug is demonstrable. The insulin released from the pancreas by the action of the drug, through its effect upon the metabolism of the liver, brings about a diminished output of hepatic glucose resulting in hypoglycemia. However, it is impossible to rule out that the sulfonylureas, aside from the action of the released insulin itself, may have some direct action upon hepatic mechanisms through which the release of sugar is diminished. For example, evidence has been presented indicating that certain hepatic systems, particularly glu-JANUARY : FEBRUARY, 1958 cose-6-phosphatase, may be inhibited, thus increasing hepatic glucose retention.
One of the main obstacles in accepting this thesis as an exclusive hypothesis for the action of the sulfonylureas is the difficulty in excluding unequivocally the peripheral action of the drug. Endogenous insulin released in response to the pancreatropic action of the drug should be expected to reach the periphery and exert its customary effect there. However, experiments from many laboratories have failed to demonstrate an unquestionable insulin-like action in the periphery following the administration of these hypoglycemic agents. Indeed, the significance of the paper by Ashmore et al. lies in the demonstration that a direct comparison of the respective actions of tolbutamide and insulin upon peripheral tissues (muscle and fat) shows that they are quite different. In detail, the experiments of Ashmore et al.
show that tolbutamide action brings about a cessation of hepatic glucose output. In contrast, insulin increases it. After isotopic glucose administration the hypoglycemia following tolbutamide does not increase the decay in blood glucose specific activity greater than that of a saline control, but following insulin administration it is markedly accelerated. Furthermore, when identical blood glucose changes are produced by tolbutamide and insulin the former has no significant effect upon the incorporation of C 14 from isotopic glucose in either peripheral glycogen or fatty acids, in sharp contrast to the significant effects which insulin produces in these two metabolic reactions. From the summation of their evidence Ashmore et al. conclude that the action of tolbutamide appears to be limited to the pancreas and the liver.
In general, these conclusions are in conformity with the experimental data published by others, but there is sufficient authoritative data leading to opposite conclu-sions so as to render dogmatism dangerous. A brief summary of negative evidence for peripheral action of the sulfonylureas is outlined. Wick 2 has been unable to demonstrate an acceleration of CO 2 production in animals injected with isotopic glucose following administration of hypoglycemic agents. In thirteen normal and six diabetic patients Elrick and Purnelf were unable to show any increase of the A-V/A values following the administration of tolbutamide. In contrast, there was a significant increase in this measurement following insulin administration. Furthermore, following tolbutamide they were unable to demonstrate any enhancement of insulin action on peripheral utilization of glucose. They concluded cautiously that "it is conceivable that the action of exogenous insulin differs somewhat from that of endogenous hormone by reason of its preparation and/or route of administration." Goetz, Senn and Senn 4 reported changes in capillary blood sugar differences, and in venous potassium and inorganic phosphorus following injections of tolbutamide quite similar to the effects observed after insulin. However, in a later paper 5 they were unable to demonstrate any change in nitrogen balance or respiratory quotient in two diabetic patients: "These results do not accord with the acute experiments reported earlier which imply an effect of tolbutamide on the peripheral utilization of sugar." In the light of this they speculate upon the possibility of an acute effect of tolbutamide resulting in a blood sugar fall following insulin release whereas the chronic effect is due to the action of the tolbutamide upon the liver. The release of insulin is too small to be detected by the methods used. Frawley, Segal, Camus and Foley* were unable to show that tolbutamide accelerated the rate of disappearance of xylose and arabinose from the blood in normal male and female subjects eighteen to twenty-one years old. In contrast, insulin significantly accelerated the rate of fall of blood concentration of these pentoses: "Tolbutamide is devoid of an insulin-like action on pentose although a hypoglycemic (decreased glucose concentration) effect was obtained. These observations point to a major difference in the mechanism of the action of insulin and tolbutamide." The main action of the sulfonylureas appears to be chiefly upon the glucose metabolism of the liver. They speculate upon the possibility that the liver in some unknown manner becomes more responsive to endogenous insulin when the sulfonylureas are administered. This enhanced effect for unknown reasons is not manifest in the periphery. Renold, Martin, Boshell and Thorn 7 studied the possibility of peripheral action of tolbutamide using the following indices: intravenous glucose tolerance, serum phosphate levels and blood pyruvate levels after intravenous glucose, respiratory quotient and nitrogen balance. They were unable to find that any of these indices were changed by the administration of tolbutamide. Some effects were observed upon the levels of blood ketones and of unesterified fatty acids which resemble the effects observed after insulin. In addition, they measured plasma insulin-like activity using the method of Vallance-Owen and in no instance were they able to find any increase of this following tolbutamide administration. They conclude that "increased peripheral glucose utilization is not a major component of tolbutamide action." Recant 8 published evidence which supports the hypothesis that the primary action of the sulfonylureas is upon the metabolism of the liver. She studied the incorporation of isotopic amino acids into liver proteins, reactions which are dependent upon adequate utilization of carbohydrate by that organ. Liver slices taken from Sprague-Dawley rats were equilibrated in vitro, and the incorporation of C 14 -glycin into liver protein was measured. There was a significant increase of this in the tolbutamide-treated rats. In addition, she observed in vitro that these liver slices showed a significant decrease in hepatic glucose release and hepatic pyruvate formation when compared to slices from untreated rats. In contrast, neither the glucose uptake nor the pyruvate formation by the isolated rat diaphragm was altered following tolbutamide administration. Peripheral glucose utilization as determined from the A-V glucose difference in the human" subject was not changed by treatment with the drug. Her conclusion was that the action of tolbutamide is essentially upon the liver alone and simulates the effects of insulin. Dulin and Johnston 9 compared the action of insulin and tolbutamide upon liver and muscle glycogen. They report that tolbutamide increases liver glycogen but does not alter muscle glycogen in fasted intact animals, whereas insulin increases muscle glycogen with no significant change in liver glycogen. However, their general conclusion is that tolbutamide acts to stimulate the secretion of insulin by the 3 -cells of the pancreas. To explain the absence of peripheral insulin effects in the face of this increased secretion of endogenous insulin, they point to the fact that a constant intravenous infusion of small doses of insulin can mimic tolbutamide action by causing a significant depression of blood sugar but no change in muscle glycogen. In other words, the tolbutamide effect is due to a prolonged action causing a steady release of small amounts of insulin. Wick, Britton and Grabowski 2 using isotopic tolbutamide measured its volume of distribution after injection. The observed value was 22 per cent of the body weight, ap-proximately equal to the extracellular compartment. From this evidence they concluded that sulfonylurea can have "no intracellular action on intact muscle cells and the only possible extrahepatic action could be on the cell surface." However, sulfonylureas did not accelerate the rate of transfer of glucose into muscle cells and they concluded that it does not have direct action on this tissue. Renold, Winegrad and Froesch 10 studied the action of the arylsulfonylureas on peripheral glucose utilization in six patients with mild diabetes and in one normal subject. After glucose loading the rate of disappearance of glucose from the blood was no different after arylsulfonylurea administration than in control periods. Measurements of serum inorganic phosphate, blood pyruvate, blood lactate and urinary phosphate also failed to show changes indicative of increased peripheral glucose utilization following administration of these hypoglycemic agents. Purnell, Arai, Pratt, Ahlad and Elrick 11 employed essentially the same technic as that described in the previous paper. They found no changes in glucose tolerance and phosphorus curves following the administration of tolbutamide. These authors also studied the A-V glucose values in a series of normal and diabetic subjects and were unable to demonstrate any significant effect upon the peripheral utilization of glucose by the drug using this index as a criterion. These authors state that their experiments are not in accord with the hypothesis that the sulfonylureas increase insulin output, since this hypothesis demands increased peripheral glucose utilization. They have no resolution of this anomalous situation. In contrast, Goetz, Gilbertson and Josephson 12 determined the A-V/A ratio in a series of human cases both normal and diabetic. They found that tolbutamide, either alone or following the injection of insulin, significantly increased this ratio. In the absence of the pancreas there was no such effect. The authors state that the increase of the ratio is assumed to mean an increased carbohydrate utilization. However, an increased A-V difference does not necessarily imply a normal fate of the sugar which has disappeared. They make no attempt to reconcile their findings with the contrary findings of previous authors. In general support of the last paper is the study of the utilization of uniformly labeled C 14glucose by rats after tolbutamide by Miller, Krake and Vanderbrook. 13 These authors compared the effect of insulin and tolbutamide on the disposition of labeled blood glucose over a six-hour period. They report that both insulin and tolbutamide increased the rate of incorporation of isotopic glucose into glycogen.
It is not easy to sum this evidence in a few words.
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The preponderance of evidence supports the pancreatropic hypothesis of the action of arylsulfonylureas coupled with a secondary effect of the released insulin upon the liver. However, such a conclusion demands the formulation of subsidiary hypotheses employing tenuous concepts unsupported by experimental support. In addition, evidence apparently based upon carefully controlled work indicating that these drugs do have peripheral action, must be ignored. As usual in instances of this sort, one must close with the statement that judgment is reserved until further evidence is available.
